Early day motion 2823

Main content

Follow this EDM by:

GENENTECH AND THE USE OF LUCENTIS AND AVASTIN FOR OPHTHALMIC PURPOSES

That this House notes the positive clinical results from the use of Lucentis for ophthalmic uses; further notes that Avastin has also been found to be efficacious for similar purposes; further notes that Genentech, the manufacturer of both, has resisted the clinical use of Avastin in an ophthalmic setting; queries whether the fact that Lucentis has a cost of the order of 40 times the cost of Avastin is a matter which is influencing the manufacturer; and calls on Health Ministers to enter into discussions with Genentech as to how most effectively patients in England can have their ophthalmic issues properly medicated.

Filter EDMs by:

Total number of signatures: 3

  1. Show:

    Close

    Glossary

    Supported by:
    A list of all MPs that have signed and support the motion.
    Withdrawn:
    A list of MPs that have withdrawn their signature from the motion.

Showing 3 out of 3

Name Party Constituency Date Signed
Hancock, Mike Liberal Democrats Portsmouth South 07.03.2012
Hemming, John Liberal Democrats Birmingham Yardley 06.03.2012
Meale, Alan Labour Party Mansfield 08.03.2012